Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Woman reading the article on multiparametric MRI in prostate cancer treatments on her laptop

Use of Multiparametric MRI in Prostate Cancer Treatments: A Prospective Study

The prospective study conducted by LMU Klinikum München investigates the effectiveness of vascular-targeted photodynamic therapy (VTP) and high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer.

Using multiparametric MRI (mpMRI), ten patients were monitored over the course of one year to track anatomical changes and potential tumor recurrence.

The results show that mpMRI reliably captures changes in prostate and tumor volumes, with an initial increase in prostate volume, followed by a significant reduction after one year. A recurrence was detected in one patient.

mpMRI proves to be a valuable tool for monitoring tumor recurrence, but further validation in larger studies is required.

Read more about the study here.

Related Resources

Related Resources

Screenshot of a prostate lesion in mint Lesion

Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion

The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate…

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…